Trends in Biomarker Diagnostics for Alzheimer’s Disease - Genetic Technology

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This issue depicts the current landscape and the new trends in a series of developments associated with Alzheimer’s disease. The study is focused on biomarker diagnostics, starting with the enumeration of the principal trends in biomarker diagnostics for Alzheimer’s disease. Cutting-edge technologies including a novel immunoassay for Alzheimer’s detection, a remarkable exome sequencing technology for Alzheimer’s risk stratification, and a new blood test for Alzheimer’s disease are profiled.Keywords: Alzheimer’s disease, dementia, mild cognitive impairment, biomarker diagnostics, risk stratification, exome sequencing, single nucleotide polymorphism, companion diagnostics, personalized medicine, preci

Table of Contents

Genetic Technology--Trends in Biomarker Diagnostics for Alzheimer’s DiseaseTrend OverviewTrends in Biomarker Diagnostics for Alzheimer’s DiseaseTechnology ProfilesNovel Immunoassay for Alzheimer’s DetectionExome Sequencing Technology for Alzheimer’s Risk StratificationNew Blood Test for Alzheimer’s DiseaseStrategic PerspectivesStrategic PerspectivesAppendixPatent ScenarioPatent ScenarioIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.